Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM is a phase 1/2, interventional study registered as NCT06630624 by M.R. Meijerink, with a registry enrolment figure of 120 participants, started 2024-07-10 and due to reach its primary completion in 2029-08-01. Interventions recorded: IP-001. Conditions listed: Colorectal Cancer; Liver Metastases; Liver Metastasis Colon Cancer. Primary outcome: Maximum Tolerated Dose (MTD) (Phase 1); 1-Year Distant Progression Free Survival (DPFS) (Phase 2 part 1); Disease Control Rate (DCR) (Phase 2 part 2). Sites: Netherlands. No results are recorded here; the registry entry is the source.